Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 3/20 | 0.34 |
| ▸ | NOS1 | P29475 | 3/20 | 0.34 |
| ▸ | NOS2 | P35228 | 3/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19646984 | 0.85 | CA1 (0.52) | CA1CA2CA4CYP1A2NOS3 | |
| SCHEMBL22178631 | 0.85 | CA1 (0.52) | CA1CA2CA4CYP1A2NOS3 | |
| SCHEMBL14236535 | 0.82 | CA1 (0.54) | CA1CA2CA4CYP1A2NOS3 | |
| SCHEMBL19732518 | 0.78 | CA1 (0.48) | CA1CA2CA4CYP1A2NOS3 | |
| SCHEMBL13350315 | 0.78 | CA1 (0.48) | CA1CA2CA4CYP1A2NOS3 | |
| SCHEMBL23223204 | 0.77 | CA1 (0.44) | CA1CA2CA4CYP1A2NOS1 | |
| SCHEMBL9637783 | 0.74 | CA1 (0.45) | CA1CA2CA4CYP1A2 | |
| SCHEMBL22766036 | 0.74 | CYP1A2 (0.32) | CYP1A2NOS3NOS1NOS2SIGMAR1 | |
| SCHEMBL23057847 | 0.72 | CA1 (0.34) | CA1CA2CA4NOS1NOS2 | |
| SCHEMBL22170469 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011559-B2 | Preparation of chiral amides and amines | SUNOVION PHARMACEUTICALS INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20180016224-A1 | PREPARATION OF CHIRAL AMIDES AND AMINES | SUNOVION PHARMACEUTICALS INC. | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011559-B2 | Preparation of chiral amides and amines | PNMT, ALKBH5, ALKBH2 | CA1 425/4885CA2 1010/4885CA4 375/4885 |
| US-20180016224-A1 | PREPARATION OF CHIRAL AMIDES AND AMINES | PNMT, ALKBH2, ALKBH5 | CA1 407/4885CA2 951/4885CA4 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.